Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126875581 | 12687558 | 1 | I | 20151115 | 20151125 | 20160825 | 20160825 | PER | US-NOVOPROD-473779 | NOVO NORDISK | 60.00 | YR | A | F | Y | 0.00000 | 20160825 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126875581 | 12687558 | 1 | PS | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | 1.2 MG, QD | Y | N | ES6R169 | 22341 | 1.2 | MG | SOLUTION FOR INJECTION | QD | |||
126875581 | 12687558 | 2 | SS | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | 1.8 MG, QD | Y | N | 22341 | 1.8 | MG | SOLUTION FOR INJECTION | QD | ||||
126875581 | 12687558 | 3 | SS | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | UNK | Y | N | 22341 | SOLUTION FOR INJECTION |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126875581 | 12687558 | 1 | Type 2 diabetes mellitus |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126875581 | 12687558 | Dyspepsia | |
126875581 | 12687558 | Gastroenteritis viral | |
126875581 | 12687558 | Headache | |
126875581 | 12687558 | Nausea | |
126875581 | 12687558 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126875581 | 12687558 | 1 | 20150922 | 0 |